Sequent Scientific Limited has informed the Exchange regarding Board meeting held on August 08, 2025.
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sequent Scientific's Board, meeting on August 8, 2025, has outlined the leadership team for the combined entity after its proposed merger with Viyash Lifesciences. The NCLT Hyderabad has directed shareholder and creditor meetings to be held on August 30, 2025 as a key step in the merger approval process. Dr. Hari Babu Bodepudi, founder and CEO of Viyash (and currently a Non-Executive Director at Sequent), will be appointed as Managing Director and Group CEO of the combined business. Current Sequent MD & CEO Mr. Rajaram Narayanan will move to the role of CEO - Animal Health while continuing as a Whole-time Director. These appointments are contingent on the merger becoming effective and receiving all required statutory approvals.
This signals the merger is moving closer to completion and brings leadership clarity for the combined entity, which could boost investor confidence. Shareholders should note the transition is not yet final and depends on the NCLT outcome on August 30 and further regulatory clearances.